摘要
Abstract
Objective To investigate the clinical efficacy of recombinant human interferon α2b(RHIα2b)combined with fructose 1,6-diphosphate(FDP)in the treatment of children with rotavirus enteritis(RVE)and its protective effect on myocardium.Methods A total of 80 children with RVE admitted to our department from January 2023 to December 2024 were selected and divided into an observation group and a control group using a random number table method,with 40 cases in each group.The control group was treated with RHIα2b alone,while the observation group was given FDP in combination with RHIα2b.The clinical efficacy,immune function,myocardial enzyme spectrum,hospitalization-related indicators and safety were compared between the two groups.Results The clinical efficacy of the observation group was significantly better than that of the control group(P<0.05).After treatment,the levels of CD3+,CD4+and the ratio of CD4+/CD8+in the observation group were higher than those in the control group(P<0.05),while the levels of creatine kinase(CK),creatine kinase-MB(CK-MB)and lactate dehydrogenase(LDH)in the myocardial enzyme spectrum were lower than those in the control group(P<0.05).The length of hospital stay and antidiarrheal time of the observation group were shorter than those of the control group(P<0.05),and there was no statistically signifi-cant difference in the dehydration correction time between the two groups(P>0.05).No adverse reactions were observed in either group.Conclusion Recombinant human interferon α2b combined with fructose 1,6-diphosphate can improve the immune function of children with RVE,reduce myocardial injury,promote recov-ery,and has favorable safety.关键词
重组人干扰素α2b/1,6-二磷酸果糖/儿童/轮状病毒肠炎/心肌保护Key words
Recombinant human interferon α2b/Fructose 1,6-Diphosphate/Children/Rotavirus enteri-tis/Myocardial protection
